Mounjaro vs Wegovy: Which Weight Loss Treatment Is Right for You?

Both Mounjaro and Wegovy are effective GLP-1 medications for weight loss, but they work differently and may suit different people. Understanding the differences can help you and your prescribing pharmacist decide which might be right for you.

Side-by-Side Comparison

How They Work Differently

Mounjaro is a dual agonist, meaning it works on two hormone systems: GLP-1 and GIP. Wegovy is a single agonist, working on GLP-1 alone. This difference is key: by targeting two pathways, Mounjaro achieves stronger appetite suppression and often greater weight loss than Wegovy. Clinical trials show that at equivalent timepoints, Mounjaro typically produces 2-3 kg more weight loss than Wegovy.

Clinical Trial Results

Mounjaro trials showed weight loss of 12-15% of body weight over 22 weeks. Wegovy trials (longer studies) showed weight loss of 15-22% over 68 weeks. The key difference is the timeframe and the starting weight of participants. Direct head-to-head trials would clarify which is more effective long-term. Both medications continue producing weight loss for at least 6-12 months before reaching a plateau.

Side Effects: Mounjaro vs Wegovy

Both medications cause similar side effects: nausea, constipation or diarrhoea, and decreased appetite. Mounjaro may cause slightly more nausea due to its dual mechanism. Wegovy more commonly causes diarrhoea. Both side effects are usually manageable and improve after 4-6 weeks as your body adjusts. Either medication can be stopped if side effects are intolerable.

Dosing and Titration

Mounjaro starts at 0.2 mg and escalates every 4 weeks to a maximum of 1.5 mg. Wegovy starts at 0.25 mg and escalates to 1.0 mg. Mounjaro's higher maintenance dose reflects its greater potency. Both require careful titration to minimize side effects. Your prescribing pharmacist will guide dose escalation based on your tolerance and response.

Price Considerations

Both medications are privately prescribed through services like GLP1 Direct. Pricing varies but is typically comparable. Mounjaro may have slightly different pricing due to its newer formulation. Discuss costs with your prescribing pharmacist when choosing between them.

Cardiovascular Benefits

Wegovy has proven cardiovascular benefits in the SELECT trial, showing a 20% reduction in cardiovascular events in people with obesity and established cardiovascular disease. Mounjaro has not yet completed similar long-term cardiovascular trials, though results are expected. If you have a history of heart disease or stroke, this may influence your choice.

Who Might Suit Mounjaro Better?

• People wanting maximum appetite suppression and weight loss
• People who have tried Wegovy without sufficient weight loss
• People who prefer a medication with dual mechanisms
• People not concerned about longer-term cardiovascular data

Who Might Suit Wegovy Better?

• People with established cardiovascular disease (proven benefits)
• People who tolerate lower doses better
• People seeking longer clinical trial data
• People who had success with semaglutide for type 2 diabetes

An Honest Conclusion

Both medications are effective and safe. Mounjaro likely produces slightly more weight loss due to its dual mechanism. Wegovy has longer-term data and proven cardiovascular benefits. For most people, the choice is less important than starting medication at all. Your prescribing pharmacist will help you choose based on your health, preferences, and goals. If one medication does not suit you, switching to the other is always an option.